
What Explains China's Biotech Rise? Genomics, Data, and the Global Biotech Ecosystem
7/3/2026
0:00
1:02:22
Why is China’s biotech industry advancing so quickly? I talk with Abigail Coplin of Vassar College to unpack China’s biotech strategy, BGI, genomics, AI-driven drug discovery, gene therapies, biotech regulation, and what the U.S.-China biotech race means for innovation, national security, and the future of medicine.
- Why has China emerged so quickly as a global biotech powerhouse?
- What gives Chinese biotech companies an edge over their Western competitors?
- How did BGI become one of the world’s most influential genomics companies?
- Why are China’s gene and cell therapies advancing so rapidly?
- What should U.S. policymakers know about China's biotech industry?
Links:
- Abigail’s academic profile
- Abigail’s policy paper for the Penn Project on the Future of U.S.-China Relations: “Getting Biotechnology Right: Managing Risk and Reward Between the U.S. and China in the Life Sciences”
- Yu Zhou and Abigail Coplin. 2022. “Innovation in a Science-Based Sector: The Institutional Evolution behind China’s Emerging Biopharmaceutical Innovation Boom.” The China Review.
For transcripts and more information, check out the High Capacity newsletter.
Follow host Kyle Chan on Twitter / X.
More episodes from "High Capacity"



Don't miss an episode of “High Capacity” and subscribe to it in the GetPodcast app.








